Premium
Serum insulin‐like growth factor‐1 levels in neurodegenerative diseases
Author(s) -
Suzuki Keisuke,
Suzuki Shiho,
Ishii Yuko,
Fujita Hiroaki,
Matsubara Takeo,
Okamura Madoka,
Sakuramoto Hirotaka,
Hirata Koichi
Publication year - 2019
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13091
Subject(s) - progressive supranuclear palsy , amyotrophic lateral sclerosis , medicine , corticobasal degeneration , frontotemporal dementia , endocrinology , dementia with lewy bodies , atrophy , dopamine transporter , dementia , dopaminergic , degenerative disease , parkinson's disease , alzheimer's disease , neurodegeneration , gastroenterology , disease , dopamine
Background We investigated serum insulin‐like growth factor (IGF)‐1 levels in patients with neurodegenerative diseases and correlated these levels with clinical parameters. Methods One hundred and fifty‐six patients with neurodegenerative diseases were included in this study, and serum IGF‐1 levels were determined. Results Serum IGF‐1 levels (mean ± standard error) were not significantly different among the patients with different neurodegenerative diseases: Parkinson's disease (PD; n = 73), 112.1 ± 5.1 ng/mL; progressive supranuclear palsy (n = 15), 102.9 ± 8.3 ng/mL; multiple system atrophy (n = 22), 103.1 ± 37.6 ng/mL; Alzheimer's disease (AD; n = 18), 102.2 ± 9.4 ng/mL; amyotrophic lateral sclerosis (n = 6), 105.5 ± 27.4 ng/mL; dementia with Lewy bodies (n = 14), 82.4 ± 7.4 ng/mL; frontotemporal dementia (n = 6), 90.0 ± 17.0 ng/mL; and corticobasal syndrome (n = 2), 118.0 ± 14.0 ng/mL. In patients with PD, serum IGF‐1 levels were negatively correlated with age and modified Rankin scale (mRS) scores and positively correlated with the striatal dopamine transporter‐specific binding ratio and the frontal assessment battery score. In patients with AD, serum IGF‐1 levels were negatively correlated with age, disease duration, and mRS scores. Conclusion We found correlations of serum IGF‐1 levels with frontal lobe and striatal dopaminergic function and disability in PD patients and with disability in AD patients. The usefulness of measuring serum IGF‐1 levels for monitoring disease progression in neurodegenerative diseases requires further studies.